Surface Oncology
  • Home
  • About Us
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Partners
  • Pipeline & Programs
    • Pipeline
    • Posters & Publications
    • Clinical Trials
  • Investors & Media
    • News
      • Press Releases
      • Events
    • Stock Information
      • Stock Quote Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Governance
      • Documents and Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Resources
      • Investor FAQs
      • Information Request
      • Email Alerts
  • Contact

Tweet

Surface Oncology and Merck to collaborate on immuno-oncology study evaluating SRF617 in combination with KEYTRUDA® (pembrolizumab). Full press release here: https://t.co/Nsx62h611W

Post navigation

Previous PostPrevious Tweet
Next PostNext Tweet

Contact Us

50 Hampshire Street 8th Floor Cambridge, MA 02139
Surface Oncology
© 2023 Surface Oncology

SURFACE ONCOLOGY and the Surface Oncology logo are registered trademarks of Surface Oncology, Inc. All rights reserved.
50 Hampshire Street, 8th Floor
Cambridge, MA 02139
  • Privacy
  • Terms of Use
Twitter Community Guidelines
Connect with Surface
  • Twitter
  • LinkedIn
  • Instagram
  • Glassdoor
  • Home
  • About Us
  • Pipeline & Programs
  • Investors & Media
      « Back
    • Investors & Media
    • News
        « Back
      • News
      • Press Releases
      • Events
    • Stock Information
        « Back
      • Stock Information
      • Stock Quote Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Governance
        « Back
      • Governance
      • Documents and Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
        « Back
      • Financial Information
      • SEC Filings
    • Investor Resources
        « Back
      • Investor Resources
      • Investor FAQs
      • Information Request
      • Email Alerts
  • Contact